These three companies from the BioRegion were recognized by the Terrassa Chamber of Commerce for their strategy based on innovation, training and knowledge.
Diabetic retinopathy is the most commonly associated disease with diabetes. It has a worldwide incidence of more than 11.5 million people in Europe, USA and Japan.
Díaz-Varela will contribute his ample experience in the pharmaceutical sector, which is key as Avancell currently has a variety of projects in the licensing phase.
This is the first DPP-4 inhibitor to be approved in a single dose, without the need to adjust the dose in type-2-diabetes patients with renal or hepatic deterioration.
